# The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

> **NCT05010200** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Ashutosh Kumar Tewari** · enrollment: 27 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** PGV-001
- **BIOLOGICAL:** Poly-ICLC
- **BIOLOGICAL:** CDX-301

## Key facts

- **NCT ID:** NCT05010200
- **Lead sponsor:** Ashutosh Kumar Tewari
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-05
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05010200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05010200, "The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05010200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*